Editor-in-Chief Ufuk Demirkılıç Frequency Quarterly Abbreviation Damar Cer Derg Publisher Turkish National Vascular and Endovascular Surgery Society ISSN 1301 - 1839 E-ISSN 2149 - 1259


Turkish Journal of Vascular Surgery 2018 , Vol 27 , Issue 1
Can heparin-bounded grafts be a useful alternative to autologous veins in low extremity bypasses?
Deniz Sarp Beyazpınar1, Bahadır Gültekin1, Hakkı Tankut Akay1
1Başkent Üniversitesi Tıp Fakültesi Kalp ve Damar Cerrahisi Anabilim Dalı, Ankara, Türkiye DOI : 10.9739/tjvs.2018.59 Objectives: This study aims to investigate whether heparin-bounded grafts are a useful alternative to autologous veins in low extremity bypasses?

Patients and methods: Between January 2002 and March 2016, we retrospectively reviewed a total of 249 patients (169 males, 80 females; mean age 66.2 years; range, 55 to 73 years) who underwent above-knee femoropopliteal bypass. A heparin-bounded polytetrafluoroethylene (PTFE) graft was used in 41 patients, a standard PTFE graft in 136 patients, and a great saphenous vein graft in 72 patients. The patency rates at one, two, and third years were evaluated.

Results: The patency rates at one year were the highest in the autologous vein grafts (94.3%), followed by heparin-bounded PTFE grafts (92.1%) and standard PTFE grafts (91.4%). The patency rates at two years were 88.1%, 84.3%, and 82.1% in the autologous vein grafts, heparin-bounded PTFE grafts, and standard PTFE grafts, respectively. The patency rates at three years were 86.3%, 82.1%, and 72.1% in the autologous vein grafts, heparin-bounded PTFE grafts, and standard PTFE grafts, respectively. Correlation analysis showed that coronary artery disease, chronic renal failure, diabetes mellitus, smoking, and one artery run-off were risk factors for bypass failure.

Conclusion: According to our study results, autologous vein grafts are the most optimal grafts, while heparin-bounded PTFE grafts seem to be a better option than standard PTFE grafts. Keywords : Femoropopliteal bypass; heparin-bounded graft; patency rate; polytetrafluoroethylene vascular graft